RELMADA THERAPEUTICS, INC. - Form 8-K Summary
Business Context and Reporting Period
RELMADA THERAPEUTICS, INC. (RLMD), a Nevada corporation, filed this Current Report on Form 8-K on May 12, 2026. The filing announces a corporate update and financial results for the three months ended March 31, 2026. The company is listed on The NASDAQ Capital Market.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document states that complete unaudited condensed consolidated financial statements for the three months ended March 31, 2026, and comparative periods will be contained in the upcoming Quarterly Report on Form 10-Q.
Material Changes
No specific material changes in financial condition or operations are detailed in the text of this 8-K. The filing serves as a notification that results have been issued and a conference call was conducted on May 12, 2026.
Guidance, Outlook, and Management Commentary
Management issued a press release (Exhibit 99.1) and updated its corporate presentation (Exhibit 99.2) on May 12, 2026. These documents contain the corporate update and financial commentary. The filing notes that the information in these exhibits is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the specific financial results (revenue, net loss, cash position) in the upcoming Form 10-Q for the period ended March 31, 2026.
- Review Exhibit 99.1 (Press Release) and Exhibit 99.2 (Corporate Presentation) for detailed operational updates and guidance not included in the 8-K text.
- Confirm the date and availability of the conference call recording held on May 12, 2026.
- Monitor the filing of the Form 10-Q to obtain the unaudited financial statements referenced in Item 2.02.